Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The Landmark Series: Desmoid.

Marco Fiore1, Aimee Crago2, Rebecca Gladdy3

  • 1Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133, Milan, Italy. marco.fiore@istitutotumori.mi.it.

Annals of Surgical Oncology
|January 2, 2021
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors Associated with Time to Sarcoma Diagnosis: Results from a Global Cross-Sectional Survey by the Sarcoma Patient Advocacy Global Network (SPAGN).

Cancers·2026
Same author

Reply to: In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Treatment of retroperitoneal sarcoma in Germany between 2000 and 2022: a retrospective analysis from the German Cancer Registry Group.

Journal of cancer research and clinical oncology·2026
Same author

The Health-Related Quality of Life of German Desmoid Patients: Results from the PROSa-DES and PROSa Study.

Cancers·2026
Same author

Diagnosis and treatment of primary soft tissue sarcomas: comprehensive review.

BJS open·2026
Same author

How have gamma-secretase inhibitors changed the treatment landscape for desmoid tumors?

Expert opinion on pharmacotherapy·2026

Desmoid-type fibromatosis management is shifting towards non-operative strategies due to benign behavior and regression potential. Active surveillance and medical therapies are now key options for these challenging tumors.

Area of Science:

  • Surgical Oncology
  • Oncology
  • Tumor Biology

Background:

  • Desmoid-type fibromatosis presents unique challenges in surgical oncology due to its infiltrative nature and potential for long-term sequelae in young patients.
  • Unlike malignant tumors, desmoids lack metastatic potential, prompting a re-evaluation of traditional surgical approaches.
  • The unpredictable behavior of desmoids, including spontaneous stabilization and regression, supports the exploration of non-operative management strategies.

Purpose of the Study:

  • To review contemporary issues influencing treatment recommendations for desmoid-type fibromatosis.
  • To highlight prognostic factors, the role of active surveillance, and surgical considerations.
  • To discuss the impact of postoperative radiotherapy and recent expert consensus in managing desmoid tumors.

Related Experiment Videos

Main Methods:

  • Comprehensive review of landmark studies and expert consensus papers.
  • Analysis of contemporary issues affecting treatment decisions for desmoid patients.
  • Evaluation of prognostic factors and surveillance strategies.

Main Results:

  • Management strategies for desmoid-type fibromatosis are increasingly favoring non-operative frontline treatments.
  • Active observation is a viable option for many patients due to the potential for tumor stabilization and regression.
  • Medical therapies have demonstrated activity in treating desmoid tumors.

Conclusions:

  • The evolving understanding of desmoid-type fibromatosis behavior supports a shift towards less invasive management.
  • Prognostic factors, active surveillance, and judicious use of surgery and radiotherapy are crucial for optimal patient care.
  • Non-operative approaches, including medical therapies and observation, are becoming central to desmoid tumor management.